1. Introduction {#sec1}
===============

Polyphenols are the most abundant antioxidants in the diet. Their main dietary sources are fruits and plant-derived beverages such as fruit juices, tea, coffee, and red wine. Current evidence strongly supports a contribution of polyphenols to the prevention of cardiovascular diseases, cancers, and osteoporosis suggesting a role of these antioxidants in the prevention of neurodegenerative diseases and diabetes mellitus \[[@B1]\].

It is well established that polyphenol ingestion results in an increase of the plasma-antioxidant capacity. However, there is still some uncertainties about their efficiency to enhance the protection of cellular components, such as lipids or DNA, against oxidative stress in humans \[[@B2]\]. Polyphenols and other antioxidants were thought to protect cell constituents against oxidative damage by scavenging free radicals. However, this concept now appears to be an oversimplified view of their mode of action \[[@B3]\]. More likely, cells respond to polyphenols mainly through direct interactions with receptors or enzymes involved in signal transduction, which may result in modification of the redox status of the cell and may trigger a series of redox-dependent reactions \[[@B4]\]. This could also apply to the anticarcinogenic effects of polyphenols, which properties may be explained by many different mechanisms.

Hydroxycinnamic acids are a major class of polyphenols found in almost every plant \[[@B2]\]. The major representative of hydroxycinnamic acids is caffeic acid, which occurs in food mainly as an ester with quinic acid named chlorogenic acid (5-caffeoylquinic acid). Coffee is a major source of chlorogenic acid in the human diet; the daily intake in coffee drinkers is 0.5--1 g whereas coffee abstainers will usually ingest \<100 mg/day. Studies have shown that approximately the 33% of ingested chlorogenic acid and the 95% of caffeic acid are absorbed intestinally \[[@B5]\]. Thus, about two-thirds of ingested chlorogenic acid reach the colon where it is probably metabolized to caffeic acid \[[@B6]\].

Bioavailability data suggest that the biological effects of chlorogenic acid would become apparent after its metabolism to caffeic acid, and hence the need of studying the effects of this acid. Chlorogenic acid and caffeic acid are antioxidants *in vitro*\[[@B7]\], and they might inhibit the formation of mutagenic and carcinogenic N-nitroso compounds since they are inhibitors of the N-nitrosation reaction *in vivo*\[[@B8]\]. Furthermore, chlorogenic acid can inhibit DNA damage *in vitro*\[[@B9]\] as it inhibits lipid peroxidation-induced DNA adduct formation \[[@B10]\] and suppresses reactive oxygen species-mediated nuclear factor (NF-*κ*B), activator protein-1 (AP-1), and mitogen-activated protein kinase activation by upregulating antioxidant enzymes \[[@B11]\]. These studies suggested that coffee polyphenols are potent chemopreventive agents.

Recent meta-analyses demonstrate inverse associations between coffee intake and the risk of colon, liver, breast, and endometrial cancer \[[@B12]--[@B15]\]. Moreover, in prospective population-based cohort studies, the inverse association between coffee consumption and risk of cancer has been shown. The group of Naganuma \[[@B16]\] found that the consumption of at least one cup of coffee per day was associated with a 49% lower risk of upper gastrointestinal cancer in a Japanese population, while Wilson and collaborators \[[@B17]\] found that men who regularly drink coffee appeared to have a lower risk of developing a lethal form of prostate cancer. The lower risk was evident when consuming either regular or decaffeinated coffee. It has been proposed that the inverse association between coffee intake and colon cancer could be explained, at least in part, by the presence of chlorogenic acid in coffee \[[@B18]\]. Ganmaa et al. \[[@B19]\] observed a general protective effect of caffeine intake on breast cancer risk for both ER subtypes, but the effect was only found to be significant for ER-positive breast cancers. In this study, the association between caffeine and breast cancer was stronger among postmenopausal women with estrogen-receptor and progesterone-receptor-positive breast cancer than those with estrogen-receptor and progesterone-receptor negative breast cancer \[[@B19]\]. In another study, coffee drinking specifically reduced the risk of developing ER-negative breast cancer but not ER-positive breast cancer \[[@B20]\].

Although there is enough evidence from epidemiological data supporting that coffee seems to reduce the risk of certain cancers, the molecular mechanisms underlying the chemopreventive effects of coffee remain unknown. For this reason, the aim of our study was to determine the effect at the molecular level of coffee polyphenols at low concentrations equivalent to one cup of coffee, using as a model a human colon cancer cell line HT29 in a nutrigenomic approach. Furthermore, the effect of coffee polyphenols was also evaluated in breast cancer cells.

2. Materials and Methods {#sec2}
========================

2.1. Materials and Chemicals {#sec2.1}
----------------------------

Cells were incubated with Instant Caffeinated Coffee (ICC) (regular lyophilized instant coffee) and Caffeic acid (CA, Sigma). Compounds were dissolved either in DMSO (CA), or sterile water (ICC), and stored at −20°C.

2.2. Cell Culture {#sec2.2}
-----------------

Colon adenocarcinoma HT29 and breast cancer MCF-7 cell lines were routinely grown in Ham\'s F12 medium supplemented with 7% fetal bovine serum (FBS, both from Gibco) at 37°C in a 5% CO~2~ humidified atmosphere in 10 cm dish, or in 33 mm plate.

Cells were incubated with ICC or CA at concentrations equivalent to one cup of coffee. The concentrations used in cell incubations, 7 *μ*g/mL in H~2~O mQ for ICC and 1.68 *μ*g/mL in DMSO for CA, respectively, took into account the amount of these compounds in one cup of coffee and their distribution in a regular human body with 75% water content. These concentrations did not cause any cytotoxic effect in the cell incubations as determined by the MTT assay \[[@B21]\].

2.3. Microarrays {#sec2.3}
----------------

Gene expression was analyzed by hybridization to The GeneChip Human Genome U133A plus 2.0 microarrays from Affymetrix, containing 47,000 transcripts and variants. HT29 cells were incubated with ICC and CA for 24 h. Total RNA was prepared from triplicate samples using Speedtools Total RNA Extraction Kit (Biotools) following the recommendations of the manufacturer. RNA quality was tested by 2100 Bioanalyzer Eukaryote Total RNA Nano Series II (Agilent Technologies). Labeling, hybridization, and detection were carried out following the manufacturer\'s specifications at the IDIBAPS Genomic Service (Hospital Clínic, Barcelona).

2.4. Microarray Data Analyses {#sec2.4}
-----------------------------

Quantification was carried out with GeneSpring GX v.11.5.1 software (Agilent Technologies), which allows multifilter comparisons using data from different experiments to perform the normalization, generation of lists, and the functional classification of the differentially expressed genes. The input data was subjected to preprocess baseline transformation using the Robust Multiarray Average summarization algorithm using the median of control samples. After grouping the triplicate of each experimental condition, list of differentially expressed genes could be generated by using volcano plot analysis. The expression of each gene is reported as the ratio of the value obtained after each condition relative to control condition after normalization and statistical analysis of the data. The corrected *P* value cutoff applied was of \<0.05; then the output of this statistical analysis was filtered by fold expression, selecting specifically those genes that had a differential expression of at least 1.3-fold. Gene classification was established by the Gene Ontology database.

2.5. Common Genes between ICC and CA Treatments {#sec2.5}
-----------------------------------------------

Common genes were selected from the lists of differentially expressed genes for each treatment using Venn-Diagrams. The newly generated list contained both over and underexpressed genes.

2.6. Generation of Biological Association Networks {#sec2.6}
--------------------------------------------------

BANs were constructed with the aid of the Pathway Analysis within the GeneSpring v.11.5.1 (Agilent) as described in Selga et al. \[[@B22]\] with the list of common genes differentially expressed in both treatments. A filtered screening was processed by the program between our data and bibliographic interaction databases up to a total of 100 related genes. Network associations were confirmed in the literature.

2.7. RT Real-Time PCR {#sec2.7}
---------------------

Total RNA was extracted from HT29 cells using Ultraspec (Biotex) in accordance with the manufacturer\'s instructions.

Complementary DNA was synthesized as described in Selga et al. \[[@B23]\] and the cDNA product was used for amplification by real time PCR. STAT5B and ATF-2 mRNA levels were determined in an ABI Prism 7000 Sequence Detection System (Applied Biosystems) using 3 *μ*L of the cDNA reaction and the assays-on-demand Hs00560035_m1 for STAT5B, Hs00153179_ml for ATF-2, and Hs00356991_m1 for APRT (all from Applied Biosystems). APRT mRNA was used as an endogenous control. The reaction was performed following the manufacturers recommendations. Fold changes in gene expression were calculated using the standard ΔΔCt method.

2.8. Western Blot {#sec2.8}
-----------------

Whole extracts were obtained from 2.5 × 10^6^ control or treated cells according to Selga et al. \[[@B23]\]. Five *μ*L of the extract was used to determine protein concentration by the Bradford assay (Bio-Rad). The extracts were frozen in liquid N~2~ and stored at −80°C. Total extracts (50 *μ*g) were resolved on SDS-polyacrylamide gels and transferred to PVDF membranes (Immobilon P, Millipore) using a semidry electroblotter.

The SNAP i.d. protein detection system technology (Millipore) was used to probe the membranes. This system applies vacuum through the membrane to actively drive reagents to protein locations, unlike the traditional technique of diffusion over the membrane as a reagent transport. [Table 1](#tab1){ref-type="table"} compiles the antibodies used in the different determinations.

Signals were detected by secondary horseradish peroxidase-conjugated antibody, either anti-rabbit (1 : 5000 or 1 : 10000 dilution; Dako) or anti-mouse (1 : 2500 dilution, Amersham NIF 824) and enhanced chemiluminescence using the ECL method, as recommended by the manufacturer (Amersham). Chemiluminescence was detected with ImageQuant LAS 4000 Mini technology (GE Healthcare).

2.9. Statistical Methods {#sec2.9}
------------------------

For the RT-PCR and Western blot analyses, values are expressed as the mean ± SE of three different experiments. Data were evaluated by unpaired Student\'s *t* test, and analyses were performed using the PASW Statistics v. 18.0.0. software.

3. Results {#sec3}
==========

3.1. Effect of ICC and CA Incubations in HT29 Gene Expression {#sec3.1}
-------------------------------------------------------------

The expression profile of over 47,000 transcripts and variants included in the microarray HG U133 plus 2.0 from Affymetrix was compared between HT29 control cells and cells incubated with either CA or ICC, at nontoxic concentrations for 24 h. GeneSpring GX software v.11.5.1 was used to analyze the results. A list of differentially expressed genes by 1.3-fold with a *P* value cutoff of \<0.05 was generated as described in Methods. When HT29 cells were incubated with ICC, 57 genes were overexpressed whereas 161 genes were underexpressed. Among the overexpressed genes, 24% belonged to the Transcription factors category and 19% to Cell cycle or to Biosynthetic processes. Within the underexpressed genes, the category corresponding to cell cycle was the most affected (53% of the genes) followed by Transcription factors (19%) and Biosynthetic processes (12%). Upon incubation with CA, 12 genes were overexpressed whereas 32 genes were underexpressed. Among the overexpressed genes, 33% belonged to the Transcription factors category, 25% to Cell cycle, and 16,7% to Biosynthetic processes or immune response. Within the underexpressed genes, again the category corresponding to Cell cycle was the most affected (30% of the genes) followed by Biosynthetic processes (15%) and Transcription factors (12%). The lists of differentially expressed genes are presented as Tables [2](#tab2){ref-type="table"}, [3](#tab3){ref-type="table"}, [4](#tab4){ref-type="table"}, and [5](#tab5){ref-type="table"}. The data presented in this work have been deposited in the Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>) and are accessible through GEO series accession number \[GSM867162\].

3.2. Generation of Biological Association Networks {#sec3.2}
--------------------------------------------------

A Biological Association Network (BAN) was constructed using the Pathway Analysis within GeneSpring v.11.5.1 as described in Methods using as the starting list the common genes differentially expressed upon incubation with CA and ICC. This list included five overexpressed genes and twelve underexpressed genes ([Table 6](#tab6){ref-type="table"}). In the generated network, signal transducer and activator of transcription 5B (STAT5B) and activating transcription factor 2 (ATF-2) appeared as highly interconnected nodes ([Figure 1](#fig1){ref-type="fig"}). These two main nodes were selected for further validations. STAT5B was overexpressed with respect to the control by 23.8% in cells treated with ICC and by 33.4% in cells treated with CA, whereas ATF-2 was found underexpressed in HT29 incubated with ICC (32.5% decrease compared to the control) and with CA (26% decrease).

3.3. Validation of STAT5B and ATF-2 Changes at the mRNA and Protein Levels {#sec3.3}
--------------------------------------------------------------------------

STAT5B overexpression in HT29 cells upon incubation with CA and ICC was confirmed at the mRNA (1.16- and 1.3-fold compared to the control, respectively) and protein levels (1.5- and 1.2-fold compared to the control, respectively) (Figures [2(a)](#fig2){ref-type="fig"} and [2(c)](#fig2){ref-type="fig"}). In the case of ATF-2, the changes in mRNA levels were confirmed for both CA and ICC (0.88- and 0.86-fold compared to the control, respectively), whereas the decrease in protein levels was only observed in CA-treated cells (0.62-fold compared to the control) (Figures [2(b)](#fig2){ref-type="fig"} and [2(d)](#fig2){ref-type="fig"}).

3.4. Expression of Cyclin D1 upon Incubation with ICC and CA {#sec3.4}
------------------------------------------------------------

Cyclin D1 is overexpressed at the mRNA and protein level in over 50% of the breast cancers either in the presence or absence of gene amplification, and it is one of the most commonly overexpressed proteins in breast cancer \[[@B24], [@B25]\]. Cyclin D1 transcription is regulated by STAT5 \[[@B26]--[@B29]\] and ATF-2 \[[@B30]--[@B32]\].

We analyzed the levels of cyclin D1 by western blot in MCF-7 and HT29 cells upon incubation with ICC and CA. As shown in [Figure 3(a)](#fig3){ref-type="fig"}, incubation of MCF-7 cells with either CA and ICC led to a drastic decrease in the levels of cyclin D1 protein, together with an increase in the levels of STAT5B, but not to a decrease in the levels of ATF-2. In HT29 cells, incubation with CA did not affect cyclin D1 levels, whereas the presence of ICC led to an increase in cyclin D1 levels 3 (b).

4. Discussion {#sec4}
=============

In this work we analyzed the gene expression profile of human cancer cells treated with either ICC or CA. Caffeic acid was chosen since it is the main representative of hydroxycinnamic acids. Using microarrays we identified the differential expression of specific genes involved in several biological pathways. The changes in mRNA expression of two outlier genes, STAT5B and ATF-2, observed in the microarrays were confirmed by RT real-time PCR, and the changes in protein levels were also analyzed by Western blot. The selection of STAT5B and ATF-2 was made according to the results obtained in the construction of a biological association network. Finally, the modulation of cyclin D1, a target of STAT5B and ATF-2 transcription factors, upon incubation with coffee polyphenols was also established.

We show that ICC and the amount of CA of one cup of coffee are able to induce STAT5B mRNA and protein levels in HT29 cells. STAT5 was originally described as a prolactin-induced mammary gland factor \[[@B33]\]. The cloning of two closely related STAT5 cDNAs, from both mouse and human cDNA libraries, showed two distinct genes, STAT5A and STAT5B that encoded two STAT5 proteins \[[@B34]--[@B37]\].

In addition to prolactin, STAT5 proteins are activated by a wide variety of cytokines and growth factors, including IL-2, IL-3, IL-5, IL-7, IL-9, IL-15, granulocyte-macrophage colony-stimulating factor, erythropoietin, growth hormone, thrombopoietin, epidermal growth factor, and platelet-derived growth factor. The key function of STAT5B is to mediate the effects of growth hormone \[[@B38], [@B39]\]. Modulation of STAT5 levels or transcriptional activity has already been described in cells treated with natural compounds such as nobiletin, a citrus flavonoid \[[@B40]\], thea flavins \[[@B41]\], and silibinin, a natural polyphenolic flavonoid which is a major bioactive component of silymarin isolated from *Silybum marianum*\[[@B42]\]. Furthermore, it has been reported that butein, the major biologically active polyphenolic component of the stems of *Rhus verniciflua*, downregulated the expression of STAT3-regulated gene products such as Bcl-xL, Bcl-2, cyclin D1, and Mcl-1 \[[@B43]\].

STAT5B participates in diverse biological processes, such as growth development, immunoregulation, apoptosis, reproduction, prolactin pathway, and lipid metabolism. STAT5B deficiency is a recently identified disease entity that involves both severe growth hormone-resistant growth failure and severe immunodeficiency \[[@B44]--[@B46]\]. The induction of STAT5B expression upon incubation with CA and ICC could represent a nutritional tool to upregulate this transcription factor and suggests novel research strategies for natural therapies in Crohn\'s disease and inflammatory bowel disease in which STAT5B appears to maintain the mucosal barrier integrity and tolerance \[[@B47], [@B48]\]. In colorectal cancer both STAT5a and STAT5b play important roles in progression and downregulation of both STAT5A and STAT5B results in a gradual decrease in cell viability, predominantly attributed to G1 cell cycle arrest, and apoptotic cell death \[[@B49]\]. In this context the increase in STAT5B caused by ICC and CA would have a negative effect on colorectal cancer patients, as it would trigger cell proliferation and survival.

In human breast cancer, STAT5A/B has been shown a dual role in the mammary gland as an initiator of tumor formation as well as a promoter of differentiation of established tumors. STAT3, STAT5A, and STAT5B are overexpressed or constitutively activated in breast cancer \[[@B50]--[@B52]\] and active STAT5A/B in human breast cancer predicted favorable clinical outcome \[[@B53]\]. Prolactin receptor signal transduction through the Jak2-STAT5 pathway has been considered to be essential for proliferation and differentiation of normal mammary epithelial cells \[[@B54]--[@B56]\]. It has been shown that the levels of NUC-pYSTAT5 decreased as breast cancer progressed from normal to *in situ*, to invasive, and then to nodal metastases \[[@B57]\]. Additionally Peck et al. \[[@B57]\] found that the absence of detectable NUC-pYStat5 in tumors of patients how where under antiestrogen therapy was associated with poor breast cancer-specific survival. We analyzed STAT5B modulation through the PRL pathway in response to coffee polyphenols in a breast cancer cell line. The MCF-7 cell line was chosen because expression of the prolactin receptor is more often found in estrogen receptor-positive breast tumors \[[@B58]\]. In our conditions, incubation with CA and ICC led to an increase in STAT5B protein levels in MCF-7 cells, and this result could be the basis for a possible inclusion of coffee polyphenols in the diet of breast cancer patients.

ATF-2 is a member of the ATF-cAMP response element-binding protein (CREB) family of transcription factors that can bind to the cAMP response element (CRE) found in many mammalian gene promoters \[[@B59], [@B60]\]. ATF-2 exhibits both oncogenic and tumor suppressor functions \[[@B61]\]. CREs are found in several genes involved in the control of the cell cycle, for example, the cyclin D1 gene, and ATF-2 binding to this sequence stimulates the transcription of cyclin D1 \[[@B30], [@B31]\]. ATF-2 mediated cyclin D1 promoter induction can be stimulated by a number of growth-promoting agents, such as estrogen \[[@B31]\], hepatocyte growth factor \[[@B62]\], and regenerating gene product \[[@B63]\]. ATF-2 has been correlated with proliferation, invasion, migration, and resistance to DNA-damaging agents in breast cancer cell lines.

The downregulation of ATF-2 expression after CA and ICC incubation in HT29 cells reported here is in accordance with the observed decrease in activity of ATF-2 in gastric cells when incubating with chlorogenic acid, the precursor of caffeic acid \[[@B64]\]. Surprisingly, the validation of the protein levels showed the upregulation of ATF-2 protein with ICC, but not with CA, both in HT29 and MCF-7 cells. This differential behavior could be due to other ICC components besides CA. In this direction Rubach et al. \[[@B64]\] reported a different response in ATF-2 activity after incubation of a gastric cell line with different coffee compounds. The presence of pyrogallol, catechol, *β*N-alkanoylhydroxytryptamides, and N-methylpyridinium increased ATF-2 activity, whereas chlorogenic acid and caffeine decrease it \[[@B64]\]. In our conditions incubation of HT29 cells with ICC caused a modest decrease in ATF-2 mRNA levels. However this effect was not translated at the protein level. We hypothesize that ICC contains other polyphenols in addition to caffeic acid that are able to increase ATF-2 protein levels through an increase of the translation of its mRNA, the increase of stability of the protein or an inhibition of its degradation. In this direction several plant polyphenols such as (-)-epigallocatechins-3-gallate (EGCG), genistein, luteolin, apigenin, chrysin, quercetin, curcumin, and tannic acid have been described to possess proteasome-inhibitory activity \[[@B65], [@B66]\].

The regulation of ATF-2 transcriptional activity, mostly at the level of its phosphorylation status, has been described upon treatment of cancer cells with several natural compounds. In MCF-7 cells, the anticancer agent 3,30-Diindolylmethane, derived from *Brassica* vegetables, activates both JNK and p38 pathways, resulting in c-Jun and ATF-2 phosphorylation, and the increase of binding of the c-Jun--ATF-2 homodimers and heterodimers to the proximal regulatory element of IFN-*γ* promoter \[[@B67]\]. Biochanin-A, an isoflavone, existing in red clover, cabbage and alfalfa, has an inhibitory and apoptogenic effect on certain cancer cells by blocking the phosphorylation of p38 MAPK and ATF-2 in a dose-dependent fashion \[[@B68]\]. The JNK stress-activated pathway is one of the major intracellular signal transduction cascades involved in intestinal inflammation \[[@B69], [@B70]\], and upregulation of ATF-2 has been shown in Crohn\'s disease \[[@B71], [@B72]\]. Thus CA could represent potential therapeutical properties in different states of intestinal inflammation due to its combined effects on STAT5B and ATF-2 in HT29 cells.

Finally, the modulation of cyclin D1, a target of STAT5B and ATF-2 transcription factors, upon incubation with coffee polyphenols was established in colon and breast cancer cells. Cyclin D1 overexpression is common in colorectal cancer, but the findings regarding its prognostic value are conflicting. In a recent study, positive expression of cyclin D1 protein was detected in 95 of 169 colonic adenocarcinoma specimens, and increased cyclin D1 levels were associated with poorer prognosis \[[@B73]\]. Furthermore, there was a significant correlation between the positive expression of p-Stat5 and cyclin D1 in patients with colonic adenocarcinoma. However, in a second study, cyclin D1 overexpression was associated with improved outcome in a total of 386 patients who underwent surgical resection for colon cancer, classified as TNM stage II or III. Belt et al. \[[@B74]\] showed that low p21, high p53, low cyclin D1, and high AURKA were associated with disease recurrence in stage II and III colon cancer patients. In this context the effect of ICC on cyclin D1 levels could represent either a positive or a negative effect in colon cancer cells, depending on tumor progression. The increase in cyclin D1 levels could represent a marker of better outcome since it has been recently established that cyclin D1 expression is strongly associated with prolonged survival in male colorectal cancer and that lack of cyclin D1 is associated with a more aggressive phenotype in male patients \[[@B75]\]. However, several natural compounds such as anthocyanins, anthocyanidins, apigenin, luteolin, and fisetin have all been described to induce experimentally cell-cycle arrest and apoptosis through the decrease of cyclin D1 levels in HT29 cells \[[@B76]--[@B80]\]. In accordance to these data, the increase observed in cyclin D1 levels in HT29 cells upon incubation with ICC could probably be the consequence of the presence of different compounds other than polyphenols in ICC.

In MCF-7 breast cancer cells, cyclin D1 was downregulated upon incubation with coffee polyphenols. The rationale for the choice of MCF-7 cell line was based on the observation that although cyclin D1 overexpression is present across multiple histologic subtypes of breast cancer, it has been shown that the large majority of cyclin D1--overexpressing breast cancers are ER positive \[[@B24], [@B25], [@B81]\]. Cyclin D1 overexpression has been reported between 40 and 90% of cases of invasive breast cancer, while gene amplification is seen in about 5--20% of tumors \[[@B24], [@B81]--[@B83]\]. In cyclin D1-driven cancers, blocking cyclin D1 expression by targeting the cyclin D1 gene, RNA, or protein should increase the chances for therapeutic success. Cell culture studies have raised the possibility that certain compounds might act in this way \[[@B84], [@B85]\] and approaches to blocking cyclin D1 expression using antisense, siRNA, or related molecules specifically target the driving molecular lesion itself \[[@B86]--[@B88]\]. It is believed that compounds that modulate cyclin D1 expression could have a role in the prevention and treatment of human neoplasias. For instance, flavopiridol, a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer, induces a rapid decline in cyclin D1 steady-state protein levels \[[@B89]\]. Taking all these results together, inhibition of cyclin D1 expression appears to be a good approach for cancer treatment. In this direction our observation that coffee and caffeic acid are able to drastically reduce the expression of cyclin D1 in breast cancer cells could suggest that some coffee components could be used as a coadjuvant therapeutic tool in the treatment of breast cancer.
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![Biological association network (BAN) of differentially expressed genes in common between CA and ICC. The list of common genes between both treatments was used to construct a BAN with the Pathway Analysis software within GeneSpring v.11.5.1. An expanded network was constructed by setting an advanced filter that included the categories of binding, expression, metabolism, promoter binding, protein modification, and regulation. Only proteins are represented. The BAN shows the node genes STAT5B and ATF-2 that were further studied.](OXIMED2012-390385.001){#fig1}

![Quantitation of mRNA and protein levels for STAT5B and ATF-2 in HT29 cells. The mRNA levels of STAT5B (a) and ATF-2 (b) were determined in control HT29 cells (empty bars) and cells treated with caffeic acid (CA, filled bars) and instant caffeinated coffee (ICC, grey bars) by RT real-time PCR as described in Methods. Results are expressed in fold changes compared to the control and are the mean ± SE of 3 different experiments. \**P* \< 0.05 compared with the corresponding control. The protein levels of STAT5B (c) and ATF-2 (d) were determined in control HT29 cells (empty bars) and cells treated with caffeic acid (CA, filled bars) and instant caffeinated coffee (ICC, grey bars) by Western blot. Blots were reprobed with an antibody against *β*-actin or tubulin to normalize the results. Results represent the mean ± SE of 3 different experiments. \**P* \< 0.05 and \*\**P* \< 0.01 compared with the corresponding control.](OXIMED2012-390385.002){#fig2}

![Expression of cyclin D1 upon incubation with ICC and CA in HT29 and MCF-7 cells. (a) Quantitation of STAT5b (empty bars), ATF-2 (filled bars), and cyclin D1 (grey bars) protein levels in MCF-7 cells. The protein levels were determined in control MCF-7 cells (CNT) and cells treated with caffeic acid (CA) and instant coffee (ICC) by Western blot. Blots were reprobed with an antibody against *β*-actin to normalize the results. Results represent the mean ± SE of 3 different experiments. \**P* \< 0.05 and \*\*\**P* \< 0.001 compared with the corresponding control. (b) Quantitation of STAT5b (empty bars), ATF-2 (filled bars), and cyclin D1 (grey bars) protein levels in HT29 cells. The protein levels were determined in control HT29 cells (CNT) and cells treated with caffeic acid (CA) and instant coffee (ICC) by Western blot. Blots were reprobed with an antibody against *β*-actin to normalize the results. Results represent the mean ± SE of 3 different experiments.\**P* \< 0.05 and \*\**P* \< 0.01 compared with the corresponding control.](OXIMED2012-390385.003){#fig3}

  Antibody    Molecular weight (KDa)   Dilution used   Supplier
  ----------- ------------------------ --------------- ----------------------------------------
  STAT5B      95                       1: 200          sc-835, Santa Cruz Biotechnology Inc.
  ATF-2       72                       1: 200          sc-6233, Santa Cruz Biotechnology Inc.
  Cyclin D1   38                       1: 200          sc-8396, Santa Cruz Biotechnology Inc.
  *β*-actin   42                       1: 200          A2066, Sigma
  Tubulin     60                       1: 100          CP06, Calbiochem

###### 

List of overexpressed genes in HT29 cells upon incubation with instant caffeinated coffee.

  Gene symbol   Gene title                                                                        *P* value   FC absolute   Regulation
  ------------- --------------------------------------------------------------------------------- ----------- ------------- ------------
  CALM3         Calmodulin 3 (phosphorylase kinase, delta)                                        0.016       1.3           Up
  CDC42EP1      CDC42 effector protein (Rho GTPase binding) 1                                     0.027       1.3           Up
  FOXN3         Forkhead box N3                                                                   0.022       1.3           Up
  KIR2DL1       Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 1   0.023       1.3           Up
  ORAI2         ORAI calcium release-activated calcium modulator 2                                0.011       1.3           Up
  RAPGEF1       Rap guanine nucleotide exchange factor (GEF) 1                                    0.022       1.3           Up
  STH           Saitohin                                                                          0.031       1.3           Up
  SLC39A3       Solute carrier family 39 (zinc transporter), member 3                             0.028       1.3           Up
  ZNF397OS      Zinc finger protein 397 opposite strand                                           0.024       1.3           Up
  ZP4           Zona pellucida glycoprotein 4                                                     0.046       1.3           Up
  FGFRL1        Fibroblast growth factor receptor-like 1                                          0.035       1.31          Up
  ITGA9         Integrin, alpha 9                                                                 0.002       1.31          Up
  IRAK1         Interleukin-1 receptor-associated kinase 1                                        0.038       1.31          Up
  OBSL1         Obscurin-like 1                                                                   0.008       1.31          Up
  RPS17L4       Ribosomal protein S17-like 4                                                      0.026       1.31          Up
  STAT5B        Signal transducer and activator of transcription 5B                               0.007       1.31          Up
  TRABD         TraB domain containing                                                            0.043       1.31          Up
  MYO9B         Myosin IXB                                                                        0.041       1.32          Up
  NME7          Nonmetastatic cells 7, protein expressed in (nucleoside-diphosphate kinase)       0.037       1.32          Up
  RPS6KA4       Ribosomal protein S6 kinase, 90 kDa, polypeptide 4                                0.014       1.32          Up
  SIRPA         Signal-regulatory protein alpha                                                   0.019       1.32          Up
  TBX20         T-box 20                                                                          0.035       1.32          Up
  TCF20         Transcription factor 20 (AR1)                                                     0.022       1.32          Up
  ALDH3B1       Aldehyde dehydrogenase 3 family, member B1                                        0.005       1.33          Up
  BGN           Biglycan                                                                          0.029       1.33          Up
  GNB4          Guanine nucleotide binding-protein (G protein), b-polypeptide 4                   0.044       1.33          Up
  IFNA17        Interferon, alpha 17                                                              0.026       1.33          Up
  KY            Kyphoscoliosis peptidase                                                          0.013       1.33          Up
  SCARF1        Scavenger receptor class F, member 1                                              0.025       1.33          Up
  SERPINB8      Serpin peptidase inhibitor, clade B (ovalbumin), member 8                         0.01        1.33          Up
  FST           Follistatin                                                                       0.025       1.34          Up
  MOGAT1        Monoacylglycerol O-acyltransferase 1                                              0.009       1.34          Up
  PPARGC1A      Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha             0.015       1.34          Up
  SUCLG2        Succinate-CoA ligase, GDP-forming, beta subunit                                   0.011       1.34          Up
  SULT1B1       Sulfotransferase family, cytosolic, 1B, member 1                                  0.018       1.34          Up
  TBX10         T-box 10                                                                          0.011       1.34          Up
  ZNF503        Zinc finger protein 503                                                           0.022       1.34          Up
  HBA1          Hemoglobin, alpha 1                                                               0.04        1.35          Up
  MEPE          Matrix, extracellular phosphoglycoprotein with ASARM motif                        0.001       1.35          Up
  PPP1CB        Protein phosphatase 1, catalytic subunit, beta isoform                            0.03        1.35          Up
  ARV1          ARV1 homolog (*S. cerevisiae*)                                                    0.011       1.36          Up
  BCL3          B-cell CLL/lymphoma 3                                                             0.034       1.36          Up
  CTRC          Chymotrypsin C (caldecrin)                                                        0.045       1.36          Up
  EPOR          Erythropoietin receptor                                                           0.008       1.37          Up
  HMGA1         High-mobility group AT-hook 1                                                     0.039       1.37          Up
  IL19          Interleukin 19                                                                    0.018       1.38          Up
  ABCC12        ATP-binding cassette, subfamily C (CFTR/MRP), member 12                           6.00E-04    1.39          Up
  RAI1          Retinoic acid induced 1                                                           0.017       1.39          Up
  KLF5          Kruppel-like factor 5 (intestinal)                                                0.028       1.4           Up
  CBWD1         COBW domain containing 1                                                          0.044       1.41          Up
  ASAH3         N-acylsphingosine amidohydrolase (alkaline ceramidase) 3                          0.039       1.43          Up
  ABHD14B       Abhydrolase domain containing 14B                                                 0.03        1.45          Up
  TLN1          Talin 1                                                                           0.049       1.45          Up
  ARHGAP23      Rho GTPase-activating protein 23                                                  0.024       1.65          Up
  HINT3         Histidine triad nucleotide binding protein 3                                      0.002       1.77          Up
  ARHGDIA       Rho GDP dissociation inhibitor (GDI) alpha                                        0.034       1.83          Up
  CALR          Calreticulin                                                                      0.007       1.93          Up

The table shows the list of overexpressed genes by 1.3-fold with a *P* value \<0.05 obtained in cells treated with instant caffeinated coffee and includes the gene symbol for all genes, and their associated description. The ratio columns correspond to the absolute fold change in expression relative to the control group and the type of regulation (up: upregulation).

###### 

List of underexpressed genes in HT29 cells upon incubation with instant coffee.

  Gene symbol   Gene title                                                     *P* value   FC absolute   Regulation
  ------------- -------------------------------------------------------------- ----------- ------------- ------------
  ACBD5         Acyl-coenzyme A binding domain containing 5                    0.017       1.3           Down
  CXADR         Coxsackie virus and adenovirus receptor                        0.015       1.3           Down
  FANCD2        Fanconi anemia, complementation group D2                       0.047       1.3           Down
  FRYL          FRY-like                                                       0.039       1.3           Down
  NUB1          Negative regulator of ubiquitin-like proteins 1                0.029       1.3           Down
  PBRM1         Polybromo 1                                                    0.004       1.3           Down
  PRKACB        Protein kinase, cAMP-dependent, catalytic, beta                0.033       1.3           Down
  RIF1          RAP1 interacting factor homolog (yeast)                        0.012       1.3           Down
  SLC39A6       Solute carrier family 39 (zinc transporter), member 6          0.022       1.3           Down
  TMEM170       Transmembrane protein 170                                      0.032       1.3           Down
  WDR26         WD repeat domain 26                                            0.028       1.3           Down
  RNGTT         RNA guanylyltransferase and 5^′^-phosphatase                   0.04        1.3           Down
  CTDSPL2       CTD small phosphatase like 2                                   0.03        1.3           Down
  ZC3H11A       Zinc finger CCCH-type containing 11A                           0.014       1.3           Down
  TMOD3         Tropomodulin 3 (ubiquitous)                                    0.0171      1.3           Down
  CPD           Carboxypeptidase D                                             0.002       1.31          Down
  CBL           Cas-Br-M ecotropic retroviral transforming sequence            0.008       1.31          Down
  CDC42SE2      CDC42 small effector 2                                         0.022       1.31          Down
  CLN5          Ceroid-lipofuscinosis, neuronal 5                              0.001       1.31          Down
  DDX3X         DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked             0.027       1.31          Down
  FGFR1OP2      FGFR1 oncogene partner 2                                       0.049       1.31          Down
  LRRFIP1       Leucine-rich repeat (in FLII) interacting protein 1            0.026       1.31          Down
  PDCD4         Programmed cell death 4                                        0.005       1.31          Down
  REPS2         RALBP1-associated Eps domain containing 2                      0.046       1.31          Down
  SLC7A6        Solute carrier family 7, member 6                              0.002       1.31          Down
  TFRC          Transferrin receptor (p90, CD71)                               0.038       1.31          Down
  TMEM19        Transmembrane protein 19                                       0.024       1.31          Down
  AGPS          Alkylglycerone phosphate synthase                              0.001       1.31          Down
  SLC4A7        Solute carrier family 4, member 7                              0.028       1.31          Down
  SPTAN1        Spectrin, alpha, nonerythrocytic 1 (alpha-fodrin)              0.02        1.31          Down
  GPD2          Glycerol-3-phosphate dehydrogenase 2 (mitochondrial)           0.033       1.31          Down
  BICD1         Bicaudal D homolog 1 (*Drosophila*)                            0.008       1.31          Down
  FBXW11        F-box and WD repeat domain containing 11                       0.025       1.31          Down
  BCLAF1        BCL2-associated transcription factor 1                         0.025       1.32          Down
  CDH1          Cadherin 1, type 1, E-cadherin (epithelial)                    0.011       1.32          Down
  CLK4          CDC-like kinase 4                                              0.049       1.32          Down
  PTAR1         Protein prenyltransferase alpha subunit repeat containing 1    0.027       1.32          Down
  SMEK2         SMEK homolog 2, suppressor of mek1 (*Dictyostelium*)           0.012       1.32          Down
  CEPT1         Choline/ethanolamine phosphotransferase 1                      0.038       1.32          Down
  SAR1A         SAR1 gene homolog A (*S. cerevisiae*)                          0.033       1.32          Down
  PDGFC         Platelet-derived growth factor C                               0.02        1.32          Down
  NFAT5         Nuclear factor of activated T-cells 5, tonicity responsive     0.045       1.32          Down
  FRS2          Fibroblast growth factor receptor substrate 2                  0.03        1.32          Down
  BMS1P5        BMS1 pseudogene 5                                              0.036       1.33          Down
  GLS           Glutaminase                                                    5.00E-04    1.33          Down
  LMAN1         Lectin, mannose binding, 1                                     7.00E-04    1.33          Down
  ARHGAP18      Rho GTPase-activating protein 18                               8.00E-04    1.33          Down
  ARHGAP5       Rho GTPase-activating protein 5                                0.006       1.33          Down
  CCNE2         Cyclin E2                                                      0.036       1.33          Down
  SPCS3         Signal peptidase complex subunit 3 homolog (*S. cerevisiae*)   0.008       1.33          Down
  NCOA2         Nuclear receptor coactivator 2                                 0.005       1.33          Down
  SRPRB         Signal recognition particle receptor, B subunit                0.018       1.33          Down
  TLK1          Tousled-like kinase 1                                          0.04        1.33          Down
  NCOA3         Nuclear receptor coactivator 3                                 0.048       1.33          Down
  STRN3         Striatin, calmodulin-binding protein 3                         2.00E-04    1.33          Down
  AP1G1         Adaptor-related protein complex 1, gamma 1 subunit             0.004       1.34          Down
  B3GALNT2      Beta-1,3-N-acetylgalactosaminyltransferase 2                   0.034       1.34          Down
  PPHLN1        Periphilin 1                                                   2.00E-04    1.34          Down
  SNX13         Sorting nexin 13                                               0.001       1.34          Down
  TMED2         Transmembrane emp24 domain-trafficking protein 2               0.041       1.34          Down
  BRWD1         Bromodomain and WD repeat domain containing 1                  0.011       1.34          Down
  HLA-B         Major histocompatibility complex, class I, B                   0.028       1.34          Down
  CHP           Calcium-binding protein P22                                    0.002       1.34          Down
  MTMR9         Myotubularin-related protein 9                                 0.026       1.34          Down
  DCUN1D4       DCN1, defective in cullin neddylation 1, domain containing 4   0.031       1.34          Down
  ARL6IP2       ADP-ribosylation factor-like 6 interacting protein 2           0.02        1.35          Down
  GLIS3         GLIS family zinc finger 3                                      0.01        1.35          Down
  LARP4         La ribonucleoprotein domain family, member 4                   0.019       1.35          Down
  PTPLB         Protein tyrosine phosphatase-like member b                     0.036       1.35          Down
  TRAM1         Translocation-associated membrane protein 1                    0.002       1.35          Down
  TMEM64        Transmembrane protein 64                                       0.001       1.35          Down
  CBFB          Core-binding factor, beta subunit                              0.005       1.35          Down
  SELT          Selenoprotein T                                                0.002       1.35          Down
  PEX13         Peroxisome biogenesis factor 13                                0.011       1.35          Down
  TNKS2         TRF1-interacting ankyrin-related ADP-ribose polymerase 2       0.034       1.35          Down
  TMPO          Thymopoietin                                                   0.001       1.35          Down
  LIN7C         Lin-7 homolog C (*C. elegans*)                                 0.007       1.35          Down
  MTA2          Metastasis-associated 1 family, member 2                       0.013       1.36          Down
  TMEM168       Transmembrane protein 168                                      0.035       1.36          Down
  CREBZF        CREB/ATF bZIP transcription factor                             0.016       1.36          Down
  OSTF1         Osteoclast-stimulating factor 1                                0.002       1.36          Down
  WDR57         WD repeat domain 57 (U5 snRNP specific)                        0.001       1.36          Down
  GLT25D1       Glycosyltransferase 25 domain containing 1                     0.008       1.36          Down
  NAPG          N-ethylmaleimide-sensitive factor attachment protein, gamma    0.015       1.36          Down
  CCDC126       Coiled-coil domain containing 126                              0.039       1.37          Down
  LASS6         LAG1 homolog, ceramide synthase 6                              0.005       1.37          Down
  MYSM1         Myb-like, SWIRM and MPN domains 1                              0.021       1.37          Down
  CYP51A1       Cytochrome P450, family 51, subfamily A, polypeptide 1         0.007       1.37          Down
  PDE4DIP       Phosphodiesterase 4D interacting protein (myomegalin)          0.024       1.37          Down
  SAP30L        SAP30-like                                                     0.012       1.37          Down
  PTPRJ         Protein tyrosine phosphatase, receptor type, J                 0.011       1.37          Down
  PGGT1B        Protein geranylgeranyltransferase type I, beta subunit         9.00E-04    1.37          Down
  ASPH          Aspartate beta-hydroxylase                                     0.011       1.37          Down
  SEMA3C        Sema domain, (semaphorin) 3C                                   0.036       1.38          Down
  WDR76         WD repeat domain 76                                            0.016       1.38          Down
  ATP13A3       ATPase-type 13A3                                               0.002       1.38          Down
  LMBR1         Limb region 1 homolog (mouse)                                  0.014       1.38          Down
  GLUD1         Glutamate dehydrogenase 1                                      0.001       1.39          Down
  GSTCD         Glutathione S-transferase, C-terminal domain containing        0.029       1.39          Down
  SPTLC1        Serine palmitoyltransferase, subunit 1                         0.02        1.39          Down
  U2AF1         U2 small nuclear RNA auxiliary factor 1                        9.00E-04    1.39          Down
  UHMK1         U2AF homology motif (UHM) kinase 1                             0.007       1.39          Down
  ARGLU1        Arginine and glutamate-rich 1                                  6.00E-04    1.39          Down
  ANKRD12       Ankyrin repeat domain 12                                       0.03        1.39          Down
  PPP3R1        Protein phosphatase 3, regulatory subunit B, alpha isoform     0.023       1.39          Down
  XRN1          5^′^-3^′^ exoribonuclease 1                                    0.019       1.4           Down
  CLSPN         Claspin homolog (*Xenopus laevis*)                             0.013       1.4           Down
  CXADRP1       Coxsackie virus and adenovirus receptor pseudogene 1           0.034       1.4           Down
  G3BP1         GTPase-activating protein- (SH3 domain) binding protein 1      0.002       1.4           Down
  TMEM30A       Transmembrane protein 30A                                      0.01        1.4           Down
  CLCN3         Chloride channel 3                                             0.035       1.41          Down
  STK4          Serine/threonine kinase 4                                      0.039       1.41          Down
  ZNF644        Zinc finger protein 644                                        0.02        1.41          Down
  TCP11L1       T-complex 11 (mouse)-like 1                                    0.014       1.41          Down
  SFRS6         Splicing factor, arginine/serine-rich 6                        0.031       1.41          Down
  NPL           N-acetylneuraminate pyruvate lyase                             0.006       1.41          Down
  G3BP2         GTPase-activating protein- (SH3 domain) binding protein 2      0.001       1.42          Down
  HNRNPU        Heterogeneous nuclear ribonucleoprotein U                      0.01        1.42          Down
  TBL1XR1       Transducin (beta)-like 1 X-linked receptor 1                   0.001       1.42          Down
  PHTF2         Putative homeodomain transcription factor 2                    0.002       1.42          Down
  ADAM10        ADAM metallopeptidase domain 10                                0.011       1.43          Down
  ADAM9         ADAM metallopeptidase domain 9 (meltrin gamma)                 0.01        1.43          Down
  MALAT1        Metastasis-associated lung adenocarcinoma transcript 1         0.04        1.43          Down
  SCARB2        Scavenger receptor class B, member 2                           0.001       1.43          Down
  CANX          Calnexin                                                       0.043       1.43          Down
  CASP2         Caspase 2, apoptosis-related cysteine peptidase                0.033       1.43          Down
  TRPS1         Trichorhinophalangeal syndrome I                               0.005       1.44          Down
  ZFX           Zinc finger protein, X-linked                                  0.033       1.44          Down
  SGPL1         Sphingosine-1-phosphate lyase 1                                0.04        1.44          Down
  PTPN11        Protein tyrosine phosphatase, nonreceptor type 11              0.045       1.44          Down
  SFRS11        Splicing factor, arginine/serine-rich 11                       0.045       1.45          Down
  B3GNT5        Beta-1,3-N-acetylglucosaminyltransferase 5                     0.021       1.45          Down
  MAP3K1        Mitogen-activated protein kinase kinase kinase 1               0.019       1.45          Down
  SNHG4         Small nucleolar RNA host gene (nonprotein coding) 4            0.004       1.46          Down
  PARD6B        Par-6 partitioning defective 6 homolog beta (*C. elegans*)     0.04        1.46          Down
  ROD1          ROD1 regulator of differentiation 1 (*S. pombe*)               0.001       1.46          Down
  SPTBN1        Spectrin, beta, nonerythrocytic 1                              0.02        1.48          Down
  TXNDC1        Thioredoxin domain containing 1                                0.013       1.48          Down
  ATF2          Activating transcription factor 2                              0.005       1.48          Down
  RDX           Radixin                                                        0.043       1.48          Down
  SCAMP1        Secretory carrier membrane protein 1                           0.009       1.48          Down
  PTAR1         Protein prenyltransferase alpha subunit repeat containing 1    0.018       1.49          Down
  RC3H2         Ring finger and CCCH-type zinc finger domains 2                0.0037      1.49          Down
  ADAM17        ADAM metallopeptidase domain 17                                0.007       1.49          Down
  FAM76B        Family with sequence similarity 76, member B                   0.014       1.5           Down
  ITGB8         Integrin, beta 8                                               1.00E-04    1.5           Down
  TRIM23        Tripartite motif-containing 23                                 0.005       1.5           Down
  CASC5         Cancer susceptibility candidate 5                              0.019       1.52          Down
  SLC16A1       Solute carrier family 16, member 1                             0.002       1.52          Down
  FNBP1         Formin-binding protein 1                                       0.037       1.53          Down
  PRKAR1A       Protein kinase, cAMP-dependent, regulatory, type I, alpha      9.00E-04    1.53          Down
  B4GALT1       Beta 1,4-galactosyltransferase, polypeptide 1                  0.035       1.55          Down
  MDM4          Mdm4 p53-binding protein homolog (mouse)                       0.011       1.58          Down
  FGD4          FYVE, RhoGEF, and PH domain containing 4                       0.001       1.59          Down
  UBA6          Ubiquitin-like modifier activating enzyme 6                    8.00E-04    1.62          Down
  ZDHHC21       Zinc finger, DHHC-type containing 21                           0.036       1.64          Down
  REEP3         Receptor accessory protein 3                                   7.00E-04    1.65          Down
  SSR3          Signal sequence receptor, gamma                                0.014       1.65          Down
  ZDHHC20       Zinc finger, DHHC-type containing 20                           0.003       1.66          Down
  EIF2S3        Eukaryotic translation initiation factor 2, subunit 3 gamma    0.001       1.7           Down
  HNRNPH1       Heterogeneous nuclear ribonucleoprotein H1                     0.011       1.79          Down
  ATL3          Atlastin 3                                                     0.001       2.02          Down

The table shows the list of underexpressed genes by 1.3-fold with a *P* value \<0.05 obtained in cells treated with instant caffeinated coffee and includes the gene symbol for all genes, and their associated description. The ratio columns correspond to the absolute fold change in expression relative to the control group and the type of regulation (down: downregulation).

###### 

List of overexpressed genes in HT29 cells upon incubation with caffeic acid.

  Gene symbol   Gene title                                                     *P* value   FC absolute   Regulation
  ------------- -------------------------------------------------------------- ----------- ------------- ------------
  SULT1B1       Sulfotransferase family, cytosolic, 1B, member 1               0.02        1.3           Up
  BCL6B         B-cell CLL/lymphoma 6, member B (zinc finger protein)          3.00E-04    1.3           Up
  KCNJ5         Potassium inwardly-rectifying channel, subfamily J, member 5   0.01        1.31          Up
  EPOR          Erythropoietin receptor                                        0.02        1.32          Up
  DNAJC21       DnaJ (Hsp40) homolog, subfamily C, member 21                   0.049       1.33          Up
  STAT5B        Signal transducer and activator of transcription 5B            0.012       1.33          Up
  FST           Follistatin                                                    0.021       1.37          Up
  CD84          CD84 molecule                                                  0.033       1.37          Up
  THRA          Thyroid hormone receptor, alpha                                0.017       1.37          Up
  MAPK8IP3      Mitogen-activated protein kinase 8 interacting protein 3       0.028       1.4           Up
  SIAE          Sialic acid acetylesterase                                     0.01        2.42          Up
  HINT3         Histidine triad nucleotide-binding protein 3                   0.033       2.6           Up

The table shows the list of overexpressed genes by 1.3-fold with a *P* value \<0.05 obtained in cells treated with caffeic acid and includes the gene symbol for all genes, their associated description. The ratio columns correspond to the absolute fold change in expression relative to the control group and the type of regulation (up: upregulation).

###### 

List of underexpressed genes in HT29 cells upon incubation with caffeic acid.

  Gene symbol   Gene title                                                  *P* value   FC absolute   Regulation
  ------------- ----------------------------------------------------------- ----------- ------------- ------------
  MFSD7         Major facilitator superfamily domain containing 7           1.00E-04    1.3           Down
  MSI2          Musashi homolog 2 (*Drosophila*)                            0.027       1.3           Down
  CDA           Cytidine deaminase                                          2.00E-04    1.31          Down
  DEFB1         Defensin, beta 1                                            0.026       1.31          Down
  PIP5K1A       Phosphatidylinositol-4-phosphate 5-kinase, type I, alpha    0.027       1.31          Down
  ZDHHC20       Zinc finger, DHHC-type containing 20                        0.005       1.31          Down
  ZDHHC21       Zinc finger, DHHC-type containing 21                        0.016       1.31          Down
  SLC4A7        Solute carrier family 4, member 7                           0.0249      1.32          Down
  CEACAM1       Carcinoembryonic antigen-related cell adhesion molecule 1   0.0459      1.32          Down
  PDZRN3        PDZ domain containing RING finger 3                         0.002       1.32          Down
  WDR62         WD repeat domain 62                                         0.005       1.32          Down
  FAM76B        Family with sequence similarity 76, member B                0.036       1.32          Down
  TCF21         Transcription factor 21                                     0.029       1.33          Down
  TBL1XR1       Transducin (beta)-like 1 X-linked receptor 1                6.00E-04    1.33          Down
  CLK4          CDC-like kinase 4                                           0.021       1.33          Down
  CYP2A13       Cytochrome P450, family 2, subfamily A, polypeptide 13      0.009       1.34          Down
  CXCR4         Chemokine (C-X-C motif) receptor 4                          0.0488      1.34          Down
  ATF2          Activating transcription factor 2                           0.0158      1.35          Down
  PDE10A        Phosphodiesterase 10A                                       0.03        1.35          Down
  METT10D       Methyltransferase 10 domain containing                      0.003       1.35          Down
  PRMT2         Protein arginine methyltransferase 2                        7.00E-04    1.36          Down
  GLS           Glutaminase                                                 5.70E-04    1.37          Down
  SLC38A5       Solute carrier family 38, member 5                          0.043       1.37          Down
  TINAG         Tubulointerstitial nephritis antigen                        0.043       1.38          Down
  AQP1          Aquaporin 1 (Colton blood group)                            0.0221      1.4           Down
  JMJD6         Jumonji domain containing 6                                 0.004       1.4           Down
  SAP30L        SAP30-like                                                  0.021       1.4           Down
  FGD4          FYVE, RhoGEF, and PH domain containing 4                    0.026       1.52          Down
  S100A2        S100 calcium-binding protein A2                             0.005       1.53          Down
  CTSZ          Cathepsin Z                                                 0.045       1.53          Down
  SLC4A4        Solute carrier family 4, member 4                           9.00E-04    1.54          Down
  AGR3          Anterior gradient homolog 3 (*Xenopus laevis*)              0.011       1.69          Down

The table shows the list of underexpressed genes by 1.3-fold with a *P* value \<0.05 obtained in cells treated with caffeic acid and includes the gene symbol for all genes, their associated description. The ratio columns correspond to the absolute fold change in expression relative to the control group and the type of regulation (down: downregulation).

###### 

Common differentially expressed genes in HT29 treated-cells.

  Gene symbol   FC absolute ICC   *P* value   Regulation   FC absolute CA   *P* value   Regulation
  ------------- ----------------- ----------- ------------ ---------------- ----------- ------------
  FST           1.343             0.025       Up           1.375            0.022       Up
  SULT1B1       1.349             0.018       Up           1.304            0.020       Up
  EPOR          1.372             0.008       Up           1.321            0.021       Up
  HINT3         2.410             0.040       Up           2.607            0.033       Up
  **STAT5B**    **1.312**         **0.007**   **Up**       **1.334**        **0.012**   **Up**
  GLS           1.335             0.001       Down         1.370            0.001       Down
  PPP3R1        1.397             0.023       Down         1.423            0.026       Down
  **ATF2**      **1.481**         **0.005**   **Down**     **1.354**        **0.016**   **Down**
  SLC4A7        1.314             0.029       Down         1.322            0.025       Down
  MARCH3        1.330             0.016       Down         1.319            0.005       Down
  TBL1XR1       1.426             0.001       Down         1.332            0.001       Down
  SAP30L        1.375             0.013       Down         1.405            0.021       Down
  FGD4          1.593             0.001       Down         1.523            0.027       Down
  ZDHHC20       1.665             0.004       Down         1.314            0.005       Down
  ZDHHC21       1.642             0.037       Down         1.318            0.016       Down
  FAM76B        1.506             0.014       Down         1.325            0.037       Down
  CLK4          1.326             0.049       Down         1.339            0.021       Down

Common differentially expressed genes in HT29 treated-cells with a *P* value \<0.05 and a minimum fold of 1.3. Column ICC correspond to cells treated with instant caffeinated coffee and column CA corresponds to cells treated with caffeic acid. Overexpressed genes are indicated on the upper part of the table, whereas underexpressed genes are depicted in the lower part. The genes in bold, STAT5B and ATF-2, were chosen for further analysis.
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